Acute Manic Or Mixed Episodes In Bipolar Disorder Therapeutics
1. Geodon patent expiration
Treatment: Treatment of bipolar disorder
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6150366 | VIATRIS | Ziprasidone formulations |
May, 2019
(6 years ago) | |
| US5312925 | VIATRIS | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
Sep, 2012
(13 years ago) | |
| US6245766 | VIATRIS | Method of treating psychiatric conditions |
Dec, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-615) | Nov 20, 2012 |
| M(M-232) | Jan 28, 2025 |
Drugs and Companies using ZIPRASIDONE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 February, 2001
Dosage: CAPSULE
How can I launch a generic of GEODON before it's drug patent expiration?
More Information on Dosage
GEODON family patents
2. Geodon patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6399777 | VIATRIS | Inclusion complexes of aryl-heterocyclic salts |
Apr, 2017
(8 years ago) | |
| US6232304 | VIATRIS | Inclusion complexes of aryl-heterocyclic salts |
Apr, 2017
(8 years ago) | |
| US6110918 | VIATRIS | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist |
Mar, 2017
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-615) | Nov 20, 2012 |
| M(M-232) | Jan 28, 2025 |
Drugs and Companies using ZIPRASIDONE MESYLATE ingredient
Market Authorisation Date: 21 June, 2002
Dosage: POWDER
More Information on Dosage
GEODON family patents
3. Geodon patent
expiration
Treatment: Treatment of bipolar disorder; Treatment of psychosis; Treatment of neuroleptic diseases
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7175855 | PFIZER INC | Ziprasidone suspension |
May, 2020
(5 years ago) | |
| US6245766 | PFIZER INC | Method of treating psychiatric conditions |
Dec, 2018
(7 years ago) | |
| US6150366 | PFIZER INC | Ziprasidone formulations |
May, 2019
(6 years ago) | |
| US5312925 | PFIZER INC | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
Sep, 2012
(13 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-615) | Nov 20, 2012 |
| M(M-232) | Jan 28, 2025 |
Drugs and Companies using ZIPRASIDONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 March, 2006
Dosage: SUSPENSION
How can I launch a generic of GEODON before it's drug patent expiration?
More Information on Dosage
GEODON family patents